Radiopharm (RADX) Fundamental Analysis: Revenue, Earnings & Valuation

1.63 / 10

Underperform

Fundamentally, RADX scores 1.6/10 (Underperform). Fixed‑asset turnover (63.6) and interest coverage (34.9) are modest positives, while inventory turnover is high. However, receivables turnover is low (0.64) and income‑tax ratio is negative, indicating weak profitability and cash conversion.

Analysis Checks(4/7)

Total operating revenue (YoY growth rate %)

Value1114.27

Score1/3

Weight20.75%

1M Return-1.40%

Inventory turnover ratio

Value106.57

Score3/3

Weight9.68%

1M Return-0.67%

Accounts receivable turnover ratio

Value0.64

Score1/3

Weight24.10%

1M Return-1.57%

Income tax / Total profit (%)

Value-0.27

Score1/3

Weight8.78%

1M Return-0.59%

Fixed assets turnover ratio

Value63.60

Score2/3

Weight15.28%

1M Return-1.01%

Interest coverage ratio (EBIT / Interest expense) (%)

Value34.91

Score2/3

Weight10.81%

1M Return-0.73%

Cost of sales ratio (%)

Value98.92

Score2/3

Weight10.61%

1M Return-0.74%

Is RADX undervalued or overvalued?

RADX scores 1.63/10 on fundamentals and holds a Premium valuation at present. Backed by its -58.11% ROE, -1298.16% net margin, -1.64 P/E ratio, 1.51 P/B ratio, and 69.30% earnings growth, these metrics solidify its Underperform investment rating.